Clinical Trial Update: A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy [Phase 2]

View source ↗

Summary

Phase II study evaluating low-dose Interleukin-2 in combination with ART versus ART alone in HIV-1 infection patients on stable ART.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Interleukin-2 (low-dose) (interleukin-2)
• antiretroviral therapy (ART) (antiretroviral therapy)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED